GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » Intrinsic Value: Projected FCF

Sinovac Biotech (Sinovac Biotech) Intrinsic Value: Projected FCF : $320.30 (As of Apr. 26, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Sinovac Biotech Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-26), Sinovac Biotech's Intrinsic Value: Projected FCF is $320.30. The stock price of Sinovac Biotech is $6.47. Therefore, Sinovac Biotech's Price-to-Intrinsic-Value-Projected-FCF of today is 0.1.

The historical rank and industry rank for Sinovac Biotech's Intrinsic Value: Projected FCF or its related term are showing as below:

SVA' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.02   Med: 3.84   Max: 13.46
Current: 0.1

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Sinovac Biotech was 13.46. The lowest was 0.02. And the median was 3.84.

SVA's Price-to-Projected-FCF is not ranked
in the Biotechnology industry.
Industry Median: 2.31 vs SVA: 0.10

Sinovac Biotech Intrinsic Value: Projected FCF Historical Data

The historical data trend for Sinovac Biotech's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech Intrinsic Value: Projected FCF Chart

Sinovac Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.12 2.73 12.38 345.47 320.30

Sinovac Biotech Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.90 345.47 71.07 320.30 65.56

Competitive Comparison of Sinovac Biotech's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Sinovac Biotech's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinovac Biotech's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinovac Biotech's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Sinovac Biotech's Price-to-Projected-FCF falls into.



Sinovac Biotech Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Sinovac Biotech's Free Cash Flow(6 year avg) = $1,980.31.

Sinovac Biotech's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec22)*0.8)/Shares Outstanding (Diluted Average)
=(14.862653310476*1980.3101428571+8921.421*0.8)/114.173
=320.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinovac Biotech  (NAS:SVA) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Sinovac Biotech's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=6.47/320.3016466284
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinovac Biotech Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinovac Biotech (Sinovac Biotech) Business Description

Industry
Traded in Other Exchanges
N/A
Address
No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.
Executives
Lily Wang director, 10 percent owner, officer: Chief Financial Officer 300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc 10 percent owner PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong director, 10 percent owner, officer: President and CEO
Terry G Bowering director, 10 percent owner, officer: President, CEO 10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6

Sinovac Biotech (Sinovac Biotech) Headlines

From GuruFocus

SINOVAC Varicella Vaccine Prequalified by WHO

By Business Wire Business Wire 11-04-2022

SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa

By Business Wire Business Wire 06-25-2022

Sinovac Amends Shareholder Rights Plan

By Business Wire Business Wire 02-22-2023